Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 5/20 | 0.48 |
| ▸ | CCND1 | P24385 | 5/20 | 0.48 |
| ▸ | GPX4 | P36969 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981465 | 0.89 | NPC1 (0.54) | TRPV1KDM4EHDAC1HDAC6FAAH | |
| SCHEMBL2972615 | 0.86 | GBA1 (0.53) | TRPV1KDM4EHDAC1HDAC6FAAH | |
| SCHEMBL2970402 | 0.86 | BAZ2B (0.47) | TRPV1KDM4EHDAC1HDAC6CDK4 | |
| SCHEMBL2970539 | 0.86 | HDAC6 (0.62) | TRPV1KDM4EHDAC1HDAC6FAAH | |
| SCHEMBL2981880 | 0.85 | BAZ2B (0.48) | TRPV1KDM4EHDAC1HDAC6 | |
| SCHEMBL8260682 | 0.79 | HDAC6 (0.57) | HDAC1HDAC6 | |
| SCHEMBL2978281 | 0.79 | CDK4 (0.42) | TRPV1FAAHCDK4CCND1GBA1 | |
| SCHEMBL2977779 | 0.78 | BAZ2B (0.55) | KDM4EHDAC1HDAC6 | |
| SCHEMBL2972415 | 0.77 | KMT2A (0.40) | KDM4E | |
| SCHEMBL2969834 | 0.77 | HTR5A (0.44) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | TRPV1 4254/4885KDM4E 691/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.